Loading clinical trials...
Loading clinical trials...
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Conditions
Interventions
BMF-219
Locations
41
United States
University of California, Irvine
Irvine, California, United States
University of Southern California Norris Cancer Center
Los Angeles, California, United States
UCLA Department of Medicine
Los Angeles, California, United States
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
Stanford Cancer Center
Stanford, California, United States
Mayo Clinic
Jacksonville, Florida, United States
Start Date
January 24, 2022
Primary Completion Date
February 13, 2025
Completion Date
May 2, 2025
Last Updated
July 3, 2025
NCT05564390
NCT07320235
NCT06782542
NCT07295951
NCT06284486
NCT07523555
Lead Sponsor
Biomea Fusion Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions